Email this article Influence of demographic characteristics on the clinical course and results of therapy in patients with precapillary pulmonary hypertension
- Authors: Taran I.N.1, Valieva Z.S.2, Belevskaya A.A.2, Saidova M.A.2, Martynyuk T.V.2,3, Chazova I.E.2
-
Affiliations:
- Research Institute for Complex Issues of Cardiovascular Diseases
- Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology
- Pirogov Russian National Research Medical University
- Issue: Vol 93, No 3 (2021)
- Pages: 283-289
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/64957
- DOI: https://doi.org/10.26442/00403660.2021.03.200655
- ID: 64957
Cite item
Full Text
Abstract
Aim. To assess the clinical course of the disease and the features of the treatment goals achievement in patients with IPAH and inoperable CTEPH depending on gender and age at the time of diagnosis verification.
Materials and methods. The study included 88 patients with IPAH and 38 patients with inoperable CTEPH with a PAWP <12 mm Hg and the duration of PAH-specific therapy treatment more than 12 months. IPAH/CTEPH patients were divided into groups depending on age at the time of diagnosis verification: age <50 years (n=69)/ >50 years (n=57), and gender: 106 women/20 men.
Results. Patients with age >50 years at the time of diagnosis verification have significantly more severe functional class (WHO). In IPAH/CTEPH male patients a significant hemodynamic disorder also as significantly higher level of NT-proBNP at the time of diagnosis verification were observed. In men with IPAH/CTEPH and patients aged >50 years more pronounced deterioration of right ventricular systolic function was observed (ECHO). Patients with IPAH younger than 50 years were significantly more likely to achieve the treatment goals by the median 26.5 months of treatment compared to the patients aged >50 years (21% vs 6.45%). Men with IPAH/CTEPH were significantly more likely to have a high risk of death (90%) at baseline compared to the women (61%).
Conclusion. IPAH/inoperable CTEPH patients with male sex, as well as the age 50 years and older at the time of diagnosis verification, compared with younger ones, are associated with a less favorable course of the disease.
Full Text
##article.viewOnOriginalSite##About the authors
Irina N. Taran
Research Institute for Complex Issues of Cardiovascular Diseases
Author for correspondence.
Email: zaviirina@mail.ru
ORCID iD: 0000-0002-4649-5921
к.м.н., науч. сотр. лаб. реабилитации отд. клинической кардиологии ФГБНУ НИИ КПССЗ
Russian Federation, KemerovoZarina S. Valieva
Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology
Email: v.zarina.v@gmail.com
к.м.н., науч. сотр. отд. легочной гипертензии и заболеваний сердца ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowAnna A. Belevskaya
Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology
Email: annabelevskaya@gmail.com
к.м.н., мл. науч. сотр. отд. ультразвуковых методов исследования ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowMarina A. Saidova
Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology
Email: m.saidova@gmail.com
проф., рук. отд. ультразвуковых методов исследования ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowTamila V. Martynyuk
Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology; Pirogov Russian National Research Medical University
Email: trukhiniv@mail.ru
д.м.н., рук. отд. легочной гипертензии и заболеваний сердца ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии», проф. каф. кардиологии ФДПО ФГБОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, Moscow; MoscowIrina E. Chazova
Myasnikov Scientific Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology
Email: zaviirina@mail.ru
ORCID iD: 0000-0002-9822-4357
акад. РАН, д.м.н., проф., зам. ген. дир. по научно-экспертной работе ИКК им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowReferences
- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23
- Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026
- Dweik RA, Rounds S, Erzurum SC, et al. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014;189(3):345-55. doi: 10.1164/rccm.201311-1954ST
- McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25):51-9. doi: 10.1016/j.jacc.2013.10.023
- Radegran G, Kjellstrom B, Ekmehag B, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014. Scand Cardiovasc J. 2016;50(4):243-50. doi: 10.1080/14017431.2016.1185532
- Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018;107(7):548-553. doi: 10.1007/s00392-018-1215-5
- Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462-8. doi: 10.1183/09031936.00049312
- Чазова И.Е., Валиева З.С., Наконечников С.Н. и др. Особенности клинико-функционального и гемодинамического профиля, лекарственной терапии и оценка прогноза у пациентов с неоперабельной хронической тромбоэмболической и идиопатической легочной гипертензией по данным Российского регистра. Терапевтический архив. 2019;91(9):77-87 [Chazova IE, Valieva ZS, Nakonechnikov SN, et al. Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(9):77-87 (In Russ.)]. doi: 10.26442/00403660.2019.09.000343
- Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi: 10.1183/13993003.51032-2015
- Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал. 2020;1:78-122 [Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Heart Journal. 2020;1:78-122 (In Russ.)]. doi: 10.24411/2076-4766-2020-10002
- Чазова И.Е., Мартынюк Т.В. от имени рабочей группы по разработке подготовке текста Российских рекомендаций по диагностике и лечению ХТЭЛГ. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (I часть). Терапевтический архив. 2016;88(9):90-101 [Chazova IE, Martynyuk TV on behalf of the Working Group on Text Preparation for russian Guidelines for the Diagnosis and Treatment of CTEPH. Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 1). Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(9):90-101 (In Russ.)]. doi: 10.17116/terarkh201688990-101
- Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33(2):318-24. doi: 10.1016/j.healun.2014.02.016
- Hjalmarsson C, Radegran G, Kylhammar D, et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51(5). doi: 10.1183/13993003.02310-2017
- Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-63. doi: 10.1161/CIRCULATIONAHA.109.911818
- Shigeta A, Tanabe N, Shimizu H, et al. Gender differences in chronic thromboembolic pulmonary hypertension in Japan. Circ J. 2008;72(12):2069-74.
- Simon MA, Deible C, Mathier MA, et al. Phenotyping the right ventricle in patients with pulmonary hypertension. Clin Transl Sci. 2009;2(4):294-9. doi: 10.1111/j.1752-8062.2009.00134.x
- Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi: 10.1016/j.echo.2016.01.011
- Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752-9. doi: 10.1378/chest.08-1758
- Jacobs W, van de Veerdonk MC, Trip P, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest. 2014;145(6):1230-6. doi: 10.1378/chest.13-1291
- Kerkhof PLM, Peace RA, Macfarlane PW. Sex- and Age-Related Reference Values in Cardiology, with Annotations and Guidelines for Interpretation. Adv Exp Med Biol. 2018;1065:677-706. doi: 10.1007/978-3-319-77932-4_41
- D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9.
- Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-56. doi: 10.1378/chest.11-1460
- Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). doi: 10.1183/13993003.00740-2017.
- Humbert M, Farber HW, Ghofrani HA et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(6). doi: 10.1183/13993003.02004-2018
- Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3). doi: 10.1183/13993003.02606-2017
- Delcroix M, Staehler G, Gall H, et al. Risk assessment in medically treated Chronic Thromboembolic Pulmonary Hypertension patients. Eur Respir J. 2018. doi: 10.1183/13993003.00248-2018
- Hoeper MM, Boucly A, Sitbon O. Age, risk and outcomes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51(5). doi: 10.1183/13993003.00629-2018
- Klinger JR, Elliott G, Levine DJ et al. Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. doi: 10.1016/j.chest.2018.11.030
- Campean IA, Lang IM. Treating pulmonary hypertension in the eldery. Expert Opin Pharmacother. 2020;31:1-7. doi: 10.1080/14656566.2020.1739270
- Barco S, Klok FA, Konstantinides SV et al. Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. J Thromb Haemost. 2020;18(1):151-61. doi: 10.1111/jth.14629
Supplementary files
